Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CNC TSE:TST NYSEARCA:XAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNCCentene$58.92+1.2%$41.56$25.08▼$62.21$29.11B1.066.60 million shs963,302 shsTSTTelesta TherapeuticsC$0.00C$0.69▼C$0.14N/AN/A212,584 shs292,300 shsXARSPDR S&P Aerospace & Defense ETF$256.96-2.4%$265.51$183.00▼$295.39$5.88B0.98291,180 shs58,651 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNCCentene-0.12%+3.25%+52.67%+41.24%-5.83%XARSPDR S&P Aerospace & Defense ETF+0.95%-2.30%-4.77%-3.77%+39.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNCCentene$58.92+1.2%$41.56$25.08▼$62.21$29.11B1.066.60 million shs963,302 shsTSTTelesta TherapeuticsC$0.00C$0.69▼C$0.14N/AN/A212,584 shs292,300 shsXARSPDR S&P Aerospace & Defense ETF$256.96-2.4%$265.51$183.00▼$295.39$5.88B0.98291,180 shs58,651 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNCCentene-0.12%+3.25%+52.67%+41.24%-5.83%XARSPDR S&P Aerospace & Defense ETF+0.95%-2.30%-4.77%-3.77%+39.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNCCentene 2.32Hold$53.82-8.65% DownsideTSTTelesta Therapeutics 0.00N/AN/AN/AXARSPDR S&P Aerospace & Defense ETF 2.73Moderate Buy$262.001.96% UpsideCurrent Analyst Ratings BreakdownLatest XAR, CNC, NXQ, and TST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026CNCCentene Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/5/2026CNCCentene JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$41.00 ➝ $52.005/5/2026CNCCentene Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$48.00 ➝ $68.005/4/2026CNCCentene TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$38.00 ➝ $47.005/1/2026CNCCentene Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$44.00 ➝ $56.004/29/2026CNCCentene OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$45.00 ➝ $58.004/29/2026CNCCentene The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell$40.004/29/2026CNCCentene BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$54.00 ➝ $63.004/29/2026CNCCentene Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$60.004/29/2026CNCCentene Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$39.00 ➝ $53.00(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNCCentene$198.10B0.15$4.74 per share12.44$40.76 per share1.45TSTTelesta TherapeuticsN/AN/AN/AN/AN/AN/AXARSPDR S&P Aerospace & Defense ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNCCentene-$6.67B-$13.14N/A13.451.13-3.25%5.57%1.54%7/28/2026 (Estimated)TSTTelesta TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AN/AXARSPDR S&P Aerospace & Defense ETFN/AN/A35.83N/AN/AN/AN/AN/AN/ALatest XAR, CNC, NXQ, and TST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/28/2026Q1 2026CNCCentene$2.23$3.37+$1.14$3.11$47.53 billion$49.94 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNCCenteneN/AN/AN/AN/AN/ATSTTelesta TherapeuticsN/AN/AN/AN/AN/AXARSPDR S&P Aerospace & Defense ETF$0.870.34%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNCCentene0.761.121.12TSTTelesta TherapeuticsN/AN/AN/AXARSPDR S&P Aerospace & Defense ETFN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNCCentene93.63%TSTTelesta TherapeuticsN/AXARSPDR S&P Aerospace & Defense ETFN/AInsider OwnershipCompanyInsider OwnershipCNCCentene0.37%TSTTelesta TherapeuticsN/AXARSPDR S&P Aerospace & Defense ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNCCentene61,100493.80 million491.97 millionOptionableTSTTelesta Therapeutics147,000N/AN/ANot OptionableXARSPDR S&P Aerospace & Defense ETFN/A22.88 millionN/ANot OptionableXAR, CNC, NXQ, and TST HeadlinesRecent News About These CompaniesSmart Investors Are Backing up the Truck on This Defense ETF at a 20% Discount42 minutes ago | 247wallst.comJapan's global defense business may be on the cusp of a big breakoutMay 13, 2026 | cnbc.comTaiwan parliament approves extra defence spending but less than government wantedMay 8, 2026 | reuters.comLeonardo Posts Strong Growth in Orders, Revenue as Europe RearmsMay 6, 2026 | wsj.comDefense stocks surge as Q1 beats fuel ETF rallyMay 6, 2026 | msn.comState Street Defense Call Perfectly Tees up Trio Of ETFs For An Incredible 2026May 5, 2026 | 247wallst.comIsrael approves plan to buy F-35 and F-15I aircraft from USMay 3, 2026 | reuters.comThe Best New Military Drones Aren't U.S.-Made. That's a Problem for the Pentagon.April 28, 2026 | barrons.comThe Pentagon is putting industry on a key 'Golden Dome' weapon that military leaders have said might ultimately be too expensiveApril 27, 2026 | businessinsider.comDefense Stocks Can Survive Big Win by Democrats in Midterms, Says CitiApril 24, 2026 | barrons.comShould You Invest in the State Street SPDR S&P Aerospace & Defense ETF (XAR)?April 23, 2026 | zacks.com3 Defense ETFs to Buy as NATO Spending Hits Record Highs in 2026April 16, 2026 | 247wallst.comThe Aerospace ETF Wall Street Overlooks: Why XAR’s Smaller Holdings Are Outrunning the GiantsApril 9, 2026 | aol.comAThe Aerospace ETF Wall Street Overlooks: Why XAR's Smaller Holdings Are Outrunning the GiantsApril 9, 2026 | 247wallst.comDefense ETFs Likely to Rally as Trump Plans Spending BoostApril 6, 2026 | zacks.comIs State Street SPDR S&P Aerospace & Defense ETF (XAR) a Strong ETF Right Now?March 31, 2026 | zacks.comSPDR S&P Aerospace & Defense ETF declares quarterly distribution of $0.1118March 23, 2026 | msn.comUS/Israel-Iran war: Which ETFs should investors watch?March 20, 2026 | msn.comDefense ETFs slip despite escalating Iran conflict: What's holding back the trade?March 20, 2026 | msn.com4 ‘Hardcore’ Defense ETFs for Leverage, Space, and Future TechMarch 5, 2026 | nai500.comNDefense Stocks Are Soaring—AeroVironment's Earnings Could Close the Gap (XAR)...March 2, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXAR, CNC, NXQ, and TST Company DescriptionsCentene NYSE:CNC$58.92 +0.69 (+1.19%) As of 11:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support. This segment also provides healthcare products. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. It also operates clinical healthcare and pharmacies, as well as offers dental and speech therapy services. In addition, the company engages in the government contracts business under the TRICARE program and other healthcare related government contracts. It provides services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in Saint Louis, Missouri.Telesta Therapeutics TSE:TSTTelesta Therapeutics Inc. is a human therapeutics company. The Company is a biotechnology company, which is focused on the licensing/acquisition and development of transformational therapeutics for the treatment of human diseases, such as cancer, immune diseases and targeted rare diseases. The Company focuses on developing drug candidate, Mycobacterium phlei cell wall-nucleic acid complex (MCNA) for the treatment of non-muscle invasive bladder cancer. The Company owns a manufacturing facility for MCNA at Montreal, Quebec. The Company has not generated any revenues.SPDR S&P Aerospace & Defense ETF NYSEARCA:XAR$256.96 -6.25 (-2.37%) As of 11:04 AM EasternThe SPDR S&P Aerospace & Defense ETF (XAR) is an exchange-traded fund that mostly invests in industrials equity. The fund tracks an equal-weighted index of US aerospace & defense companies. XAR was launched on Sep 28, 2011 and is managed by State Street. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings Rewiring AI: NextEra Energy Sparks a Mega Merger Flipping the Switch: Is Ford the Next Big Energy Stock? Does Nano Nuclear Energy’s New Deal Amp the Outlook? Dillard’s Posted a Huge Earnings Beat—So Why Did the Rally Fade? Why Trump’s Amazon Stock Sale May Not Matter at All Why Applied Optoelectronics Stock May Be Near a Turning Point Is Everspin Technologies the Next AI Edge Breakout? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
